Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,905 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 5,905 shares of Bicycle Therapeutics stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the sale, the chief executive officer directly owned 605,408 shares in the company, valued at approximately $2,585,092.16. This represents a 0.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, July 6th, Kevin Lee sold 1,737 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $4.31, for a total value of $7,486.47.

Bicycle Therapeutics Stock Up 0.7%

BCYC stock opened at $4.38 on Wednesday. The company has a market cap of $305.77 million, a price-to-earnings ratio of -1.39 and a beta of 1.55. Bicycle Therapeutics PLC Sponsored ADR has a twelve month low of $3.92 and a twelve month high of $9.18. The business has a 50 day moving average price of $4.39 and a two-hundred day moving average price of $5.26.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%.The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $7.50 million. On average, equities research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Morgan Stanley reduced their price objective on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a report on Wednesday, April 8th. Citigroup reissued a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Needham & Company LLC reduced their price target on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Citizens Jmp decreased their price objective on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a report on Wednesday, March 18th. Finally, Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $14.00.

Institutional Investors Weigh In On Bicycle Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Man Group plc grew its position in Bicycle Therapeutics by 4.8% during the fourth quarter. Man Group plc now owns 42,860 shares of the company’s stock worth $303,000 after buying an additional 1,969 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Bicycle Therapeutics by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after acquiring an additional 2,243 shares during the period. Flax Pond Capital LLC grew its holdings in shares of Bicycle Therapeutics by 1.4% during the 1st quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock worth $817,000 after purchasing an additional 2,503 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Bicycle Therapeutics by 21.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after purchasing an additional 2,668 shares in the last quarter. Finally, Clearstead Advisors LLC increased its position in shares of Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares during the period. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.